Eisai’s Alzheimer’s drug Leqembi gaining ground with US neurologists, but most waiting on full approval: Spherix
U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for the FDA’s full green light for the drug remain high barriers to uptake. That’s according to a new survey and report out by drug launch analyst Spherix Global Insights, which in March asked 73 neurologists working in […]
U.S. Neurologists Cautiously Optimistic Following Accelerated Approval and Launch of Eisai/Biogen’s Leqembi for Early Alzheimer’s Disease, According to Spherix Global Insights
Concerns about ARIA and the associated monitoring requirements for Leqembi could present significant barriers to uptake. Exton, PA., April 5, 2023 – With the accelerated approval on January 6, 2023 for early Alzheimer’s disease, Eisai/Biogen’s Leqembi (lecanemab-irmb) became only the second approved disease-modifying therapy (DMT) for early Alzheimer’s disease. Leqembi’s predecessor, Biogen’s Aduhelm (aducanumab-avwa), […]
At Fifteen Months Post-Launch, AbbVie’s Qulipta Outperforms Pfizer’s Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights
Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands’ use on par. Exton, PA., March 16, 2023 – Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch of AbbVie’s Qulipta for the preventive treatment […]
Early Launch Metrics for TG Therapeutics’ Briumvi in RMS Trail Those of Novartis’ In-Class Competitor Kesimpta, According to Spherix Global Insights
Content Area
Despite Market Access Hurdles and Limited Familiarity Hampering Initial Uptake, Neurologists Project Robust Future Use of Relyvrio for the Treatment of ALS, According to Spherix Global Insights
Recent research suggests Relyvrio will benefit from the limited number of therapies approved to slow decline in ALS Exton, PA., March 9, 2023 – With the FDA approval of Amylyx’s Relyvrio (AMX0035; sodium phenylbutyrate and taurursodiol) for amyotrophic lateral sclerosis (ALS) in September 2022, patients gained access to only the third novel molecule approved for […]
US Neurologists Cautiously Optimistic About Potential Approval of Pfizer’s Zavegepant for the Acute Treatment of Migraine, According to Spherix Global Insights
Recently released positive phase 3 data for Pfizer’s zavegepant likely to fuel already noted perceptions among prescribers that the brand will have a high responder rate. Exton, PA., February 28, 2023 – On February 16, The Lancet Neurology published the Phase 3 results of Pfizer’s zavegepant for the acute treatment of migraine. The CGRP receptor […]
One Year Post-Launch of Argenx’s Vyvgart for gMG, US Neurologists Confused on Best Approach to Treatment Dosing Schedules, According to Spherix Global Insights
Despite early satisfaction with Vyvgart, half of surveyed neurologists & neuromuscular specialists report uncertainty regarding re-dosing after the first treatment cycle Exton, PA., February 24, 2023 – Argenx’s launch of Vyvgart (efgartigimod) has been a success, with global first-year revenue of ~$400 million USD. As the second biologic approved for generalized myasthenia gravis (gMG) and […]
Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights
U.S. neurologists increasingly favor Novartis’ MS portfolio, particularly Kesimpta Exton, PA., February 17, 2023 – According to Biogen’s earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third year in a row. The company attributed the 2022 decline to generic erosion, pricing pressures, and a shift […]
Generalized Myasthenia Gravis Pipeline Assessment Unveils Top Contenders to Challenge Current Market Biologics – New Spherix Report
High interest in argenx’s SC efgartigimod, Sanofi’s tolebrutinib, Genentech’s satralizumab, and Horizon’s inebilizumab Exton, Pa., October 6, 2022 /PRNewswire/ – The recent launches of argenx’s Vyvgart and Alexion’s Ultomiris for the treatment of generalized myasthenia gravis (gMG), a debilitating and chronic autoimmune neuromuscular disorder, have provided patients with a new mechanism of action and new […]
Economic Burden Forces Shift in Specialty Physicians’ Treatment Decisions and Relationship with Pharma, According to New Spherix Report
The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and increased patient sensitivity to medication costs EXTON, Pa., September 12, 2022 /PRNewswire/ — Over the past year, many countries have reported multi-decade highs in inflation, with the United States recording its highest inflation rate in […]
